Zota Health Care Limited announced the outcome of its Board Meeting held on February 04, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. In strategic moves, the company approved the acquisition of 58,827 equity shares of its Wholly Owned Subsidiary, Davaindia Health Mart Limited, through a rights issue subscription. The acquisition cost was ₹25,29,56,100/-, with shares acquired at ₹4300/- each. Davaindia Health Mart Limited, incorporated in January 2020, operates a retail pharmacy chain with 1438 stores across India and reported a turnover of ₹109.93 crore in FY 2024-25. Furthermore, Zota Health Care approved the acquisition of a 100% stake in Curexis Ventures Private Limited by acquiring 1,00,000 equity shares for ₹10,00,000/-, at ₹10/- per share. Curexis Ventures Private Limited, incorporated in February 2025, is involved in drug manufacturing, development, and marketing, and operates retail pharmacy stores under the brand name “SKIA”. The acquisition aims to expand the company's footprint in the retail generic pharmacy chain segment. The Board also approved the constitution of a Risk Management Committee with Mr. Moxesh Ketanbhai Zota as Chairperson, Mr. Himanshu Muktilal Zota as Member, and Mr. Dhaval Chandubhai Patwa as Member.
